Apexion Health Tirzepatide treatment vial
WEIGHT LOSSGLP-1 / GIP

MONTHLY SUPPLY · 2.5MG–15MG

TIRZEPATIDE

TREATMENT

Dual GLP-1/GIP agonist for advanced weight reduction

SUPPORT

Tirzepatide activates two gut hormone receptors — GLP-1 and GIP — for weight reduction that surpasses single-pathway therapies in clinical trials, with up to 22% mean body weight reduction reported.

Shop Now

Lab-Tested · Physician-Supervised · Discreet Delivery

Apexion Health — WEIGHT LOSS

TWO RECEPTORS. ONE BREAKTHROUGH OUTCOME.

Tirzepatide is the first dual GLP-1 and GIP receptor agonist. GIP enhances and complements the GLP-1 signal — the combination produced up to 22% mean body weight reduction in clinical trials, the highest recorded for any weight-management medication. It represents a step change in what pharmacologically-assisted weight loss can achieve.

Clinical Benefits

TIRZEPATIDE SUPPORTS YOUR HEALTH AT THE CELLULAR LEVEL

  1. 01.

    DEMONSTRATED UP TO 22% MEAN BODY WEIGHT REDUCTION IN CLINICAL TRIALS

  2. 02.

    DUAL GLP-1 AND GIP RECEPTOR ACTIVATION

  3. 03.

    SUPERIOR TO SINGLE-AGONIST THERAPIES IN HEAD-TO-HEAD STUDIES

  4. 04.

    IMPROVES INSULIN SENSITIVITY AND FASTING GLUCOSE

  5. 05.

    WEEKLY DOSING WITH GRADUAL TITRATION

  6. 06.

    COMPOUNDED FORMULATION — CONSISTENT SUPPLY

Shop Now

Clinical Evidence

How It Works in the Body

01 — Dose & Efficacy

SURMOUNT-1: Weight Loss at 72 Weeks

5 mg Mean 15.0% WL50%
10 mg Mean 19.5% WL63%
15 mg Mean 20.9% WL70%

Jastreboff et al., NEJM 2022;387(3):205–216

02 — Hormone Panel

Dose-Response Impact (15 mg)

MarkerWithoutWith Treatment
Waist Circ.cm
114.3
94.7−19.6
HbA1c%
5.6
5.2−0.42
Systolic BPmmHg
127.3
120.4−6.9
Triglycerides% chg
Baseline
——−26.5%

Dual incretin mechanism drives superior efficacy

GIP/GLP-1 dual agonism produced greater weight loss than any single-agent GLP-1. At 15 mg, 91% achieved ≥5% WL, 83% ≥10%, 57% ≥20%.

Jastreboff et al., NEJM 2022;387(3):205–216

03 — Protocol

Dose Escalation Schedule

InitiationWeeks 1–4
  • ›Start 2.5 mg SC weekly
  • ›GI tolerance assessment
  • ›Weight & glucose baseline
EscalationWeeks 5–20
  • ›5 → 7.5 → 10 → 12.5 → 15 mg
  • ›Step up every 4 weeks
  • ›Monitor GI & labs
MaintenanceWeek 21+
  • ›15 mg SC weekly target
  • ›Weight q3 months
  • ›Metabolic panel q6 months

5 dose steps over 20 weeks to target

Longer escalation than semaglutide. Most GI effects mild-moderate during escalation. Discontinuation: 4.3% (5 mg), 7.1% (10 mg), 6.2% (15 mg) vs 2.6% placebo.

All protocols physician-supervised and adjusted per individual labs.